MedTrace Logo

Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

NCT06452537 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2026-01-08

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and efficacy of Tocilizumab in MOGAD.

Conditions

  • Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Interventions

DRUG

Tocilizumab

Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, with oral prednisone.

DRUG

Prednisone

Prednisone tapering protocol : If the starting dose is over 20mg/day, then reduce by one tablet weekly. Until the dose is reduced to 20mg/day then 20mg/day for two weeks→17.5mg/day for two weeks→12.5mg for four weeks→10mg for four weeks→7.5mg as a maintain dosage

Sponsors & Collaborators

  • Tianjin Medical University General Hospital

    lead OTHER

Principal Investigators

  • Chao Zhang, M.D., Ph.D · Tianjin Medical University General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-09
Primary Completion
2026-01-01
Completion
2026-07-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06452537 on ClinicalTrials.gov